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Steroid reduction provoked a relapse responding to IS. 
2 years later, she complained of right-sided blurred vision 
and floaters; both eyes showed whitish circumscribed retinal 
infiltrations, cellular infiltration of the vitreous and mild bilat-
eral optic disc edema. Oncological and neurological work-up 
ruled out infectious diseases and other GvHD manifestations. 
Symptoms and signs resolved under continued systemic IS, 
leaving pigmented retinal scars. After IS withdrawal, classical 
cutaneous cGvHD developed, resolving on systemic IS. 
94 months after transplantation, she is doing well. Conclu-
sion: To our knowledge, this is the first observation of retinal 
involvement of cerebral cGvHD manifestations with retinal 
infiltrations documented in the absence of other causes and 
in parallel to periventricular lesions in cerebral MRI. Based on 
bone marrow histology, we discuss a small vessel patho-
physiology of cGvHD.
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Summary
Background: We report a 35-year-old female patient with cer-
ebral manifestations of chronic graft-versus-host disease 
(cGvHD) and putative retinal involvement after allogeneic pe-
ripheral blood stem cell transplantation (alloHSCT). Patient 
and Methods: The patient experienced recurrent episodes of 
fever and encephalitic signs 7 months after alloHSCT during 
taper of immunosuppression (IS). Results: Cerebral magnetic 
resonance imaging (MRI) showed non-gadolinium-enhancing 
confluent periventricular lesions and cerebrospinal fluid in-
flammation. After exclusion of infectious causes, treatment 
with steroids and antiepileptics improved cognitive deficits. 
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Established Facts
• High likelihood of a chronic graft-versus-host disease (cGvHD) manifestation in the central nervous 
system (in accordance to consensus criteria) since: (1) neurological symptoms correlated closely with the 
intensity of immunosuppression (IS); (2) worsening of symptoms occurred during taper of IS; (3) other 
causes were excluded; and (4) neurological symptoms corresponded with magnetic resonance imaging 
abnormalities and abnormal cerebrospinal fluid.
Novel Insights
• First case of putative retinal involvement in a patient with cerebral manifestation of cGvHD.
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Introduction
Graft-versus-host disease (GvHD) after allogeneic peripheral 
blood stem cell transplantation (alloHSCT) can affect multiple or-
gans including skin, genital and oral mucosa, lungs, liver, muscles, 
the skeletal system, and the peripheral and central nervous system. 
Ocular involvement in chronic GvHD (cGvHD) is mainly associ-
ated with ocular surface disorders [1–3]. In rare cases, the vitreous 
and choroids are affected in acute GvHD [4]. Retinal manifestation 
of cGvHD has not been described. 
Case Report
Due to a myelodysplastic syndrome RAEB I (refractory anemia with excess 
blasts type 1), a 35-year old female patient received an alloHSCT from a human 
leukocyte antigen-matched (10/10) unrelated donor after toxicity-reduced condi-
tioning with fludarabin, BCNU (carmustine) and melphalan, and GvHD prophy-
laxis with ATG (anti-thymocyte globulin), tacrolimus and MMF (mycophenolate 
mofetil) [5]. On day 20 she developed a GvHD with cutaneous (grade 2) and upper 
gastrointestinal (grade 1) involvement that responded to steroids and etanercept. 
Over the next months, immunosuppression (IS) was reduced as planned. On 
day 159 (after withdrawal of steroids, during taper of tacrolimus), she experienced 
repeated left-sided hemihypesthesia for some minutes and presented for neurologi-
cal assessment. Clinical examination was normal, but for symmetric postural hand 
tremor. Cerebral MRI (magnetic resonance imaging; Siemens Symphony TIM, 
1.5T, Germany) was unremarkable, but electroencephalography (EEG) revealed 
diffuse slowing. Focal epileptic seizures were discussed. On day 208 after alloHSCT, 
IS was terminated. During the following 2  months, she developed intermittent 
fever and progressive personality change. After a tonic-clonic seizure, she remained 
disorientated with psychomotor slowing and reduced awareness, spontaneous nys-
tagmus to the left, generalized hypersensitivity to touch and hypesthesia in all sa-
cral dermatomes on both sides. Meningeal, and other spinal and cauda-equine 
signs were normal. There were no signs of GvHD of any other organ and no signs 
of transplantation-associated microangiopathy. EEG revealed diffuse and parietal 
left regional slowing, and cerebral MRI remained unremarkable. Analysis of the 
cerebrospinal fluid (CSF; 19  leukocytes/μl, protein 630 mg/l, with no intrathecal 
synthesis of immunoglobulins (including isoelectric focusing)) suggested an in-
flammatory disease, but no infectious cause was found systemically or in CSF (i.e. 
using bacterial and fungal cultures, tests for toxoplasmosis and pneumocystis, and 
PCR for cytomegalovirus (CMV), herpes simplex virus, varicella-zoster virus, Ep-
stein-Barr virus, human herpesvirus 6, polyomaviruses JCV and BKV, and entero-
viruses). Assuming encephalitis as the only manifestation of GvHD, treatment with 
steroids and antiepileptics was started on day 246. The cognitive deficits improved 
over the next few months and steroids were slowly reduced. On day 425, her hus-
band reported recurring mild personality changes, and 2 months later she had an-
other seizure. Cerebral magnetic resonance imaging (MRI; fig. 1) showed confluent 
periventricular lesions without gadolinium enhancement or infratentorial lesion, 
and CSF was unchanged. Thus, IS with steroids was restarted complemented with 
MMF, resulting in improvement of neurological symptoms. In 2009, seizures re-
curred in form of transient aphasia/dysarthria during reduction of steroids. Despite 
progressive periventricular lesions in cerebral MRI, she improved clinically, and 
the steroids were tapered. 
In March 2010, she complained blurred vision and floaters on the right eye 
(visual acuity 1.0/1.0). External eye and anterior segment findings were normal 
without corneal staining, but lacrimal gland function was reduced in the Schirmer 
test (4 mm). Both eyes showed whitish circumscribed retinal infiltrations in the 
mid-periphery of the fundus, cellular infiltration of the vitreous, and mild bilateral 
optic disc edema (figs. 2A and 2B). 2  years previously (i.e. 8  months after al-
loHSCT), the funduscopy had been normal. Goldmann perimetry showed regular 
visual fields despite a blind spot enlargement on the left eye. Visual evoked poten-
tials revealed bilateral delayed latency (P100 right side 121 ms, left side 124 ms, 
normal < 120 ms); MRI did not suggest optic neuritis. The oncological and neuro-
logical work-up ruled out acute infectious diseases as CMV infection or re-activa-
tion, lymphoma or leukemic manifestations, and other GvHD manifestations. 
Symptoms and signs resolved under continued systemic IS treatment with predni-
solone and MMF, leaving mildly pigmented retinal scars (fig. 2C). The patient de-
veloped multiple osteonecrotic lesions (femur and tibia) and, 4 years after trans-
plantation, mild anemia and thrombocytopenia. Bone marrow (BM) biopsy 
showed mild marrow hypoplasia, but complete donor chimerism without signs 
for myelodysplasia and normal cytogenetics. However, staining for osteopontin 
and endothelial cells (CD34) revealed a decline in vascularization within the BM 
and a significant reduction of osteopontin expression. After subsequent tapering 
and termination of IS, at 52 months after alloHSCT, the patient developed cutane-
ous cGvHD for the first time with sclerotic features, which was treated with extra-
corporal photopheresis, resulting in resolution and normalization of blood counts. 
Currently, she is alive and doing well 94 months after transplantation. 
Discussion
While cGvHD frequently involves epithelial structures and fas-
cia, it rarely involves the central nervous system (CNS) [6–8]. Since 
no specific criteria for CNS manifestation of cGvHD have been es-
tablished, the diagnosis was based on exclusion of other causes and 
response to immunosuppressive treatment [6, 8]. In accordance 
with the consensus criteria for cerebral GvHD [6, 8], the likelihood 
of a CNS manifestation of cGvHD, as explanation of symptoms of 
our patient, is high since: (1) neurological symptoms, including 
Fig. 1. Cerebral magnetic resonance imaging (MRI). (A) Day 162 after alloge-
neic peripheral blood stem cell transplantation (alloHSCT): without pathologi-
cal findings (axial T2-weighted turbo spin echo (TSE), diffusion-weighted im-
aging (DWI), T1-weighted SE post contrast). (B) Day 430: confluent periven-
tricular lesions without acute changes on DWI and no contrast enhancement 
(axial T2 TSE, DWI, T1 SE post contrast). (C) Day 1185: progressive confluat-
ing periventricular lesions without acute changes on DWI and no contrast en-
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seizures, correlated closely with the intensity of IS; (2) withdrawal 
of steroids led to worsening of symptoms; and (3) other causes 
were excluded. To our knowledge this is the first time that a puta-
tive retinal involvement of cerebral manifestations of cGvHD, with 
retinal infiltrations documented in the absence of other causes, has 
been observed. This suggests that cGvHD may involve the retina 
directly and has to be differentiated from infectious diseases (e.g. 
CMV retinitis) and retinal microangiopathy (e.g. radiation retin-
opathy), which are frequently seen in patients after HSCT [9, 10]. 
While the pathogenesis is unknown, the decline of vascularization 
observed in the BM and the retinal infiltration with subsequent 
scarring suggest a vasculitis-mediated process in our patient. In a 
murine GvHD model, a loss of osteoblasts and endothelial cells 
(explaining cytopenia and osteonecrosis) have been reported [11], 
both key components of the stem niche. Biedermann et al. [12] de-
scribed CD8+-mediated vasculitis in cutaneous cGvHD, leading to 
a loss of microvessels. The lack of acute brain infarction in the 
MRIs might be similar to the situation in vascular dementia. As 
CNS, retina and bone structures are extremely sensitive to vascular 
damage (possibly aggravated by the use of steroids causing avascu-
lar bone necrosis), these systems primarily show a diffuse vascular 
process of microvessels. In addition, the present case indicates a 
potential risk for ocular posterior pole involvement in patients 
with cerebral manifestations of cGvHD. Based on the finding for 
our patient, cerebral involvement may occur as the only clinical 
manifestation of GvHD including retinal involvement, and fun-
duscopy should be considered as a diagnostic tool.
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Fig. 2. (A) Whitish retinal and chorioretinal le-
sions in the mid-periphery of the right and left fun-
dus, mild optic disc edema and mild cellular infil-
tration of the vitreous can be seen. (B) During flu-
orescein angiography, staining of retinal/chorioret-
inal lesions and leakage at the optic disc were 
observed. Optical coherence tomography (OCT) 
scan revealed (chorio-) retinal scarring with irregu-
lar retinal cell layers. (C) Whitish, mildly pig-
mented retinal/chorioretinal scars on the right and 
left fundus can be observed. OCT scan showed 
(chorio-) retinal scarring with disorganized retinal 
layers.
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